FDA Approves Breakthrough Daily Pill for Cholesterol

What do we know about the new cholesterol pill, Lipfendra? Merck's new once-a-day drug gets FDA nod

The FDA has approved Merck's once-daily cholesterol pill Lipfendra (enlicitide), marking the first oral PCSK9 inhibitor.

Merck’s Lipfendra Pill Wins FDA Nod as First Oral PCSK9 Cholesterol Treatment

Merck just cleared a major regulatory hurdle. The FDA approved its once-daily pill Lipfendra on July 16, 2026. This marks the first oral drug in the PCSK9 inhibitor class. Patients with stubbornly high LDL cholesterol now have an alternative to injections. The decision arrives at a moment when cardiologists seek better options. Statins remain the foundation. Yet many patients need extra help to hit aggressive LDL targets. Heart disease still cla…

FDA approves breakthrough daily pill for cholesterol

The Food and Drug Administration has approved a new cholesterol‑lowering pill that could help millions of Americans. Merck’s Lipfendra, the brand name for the drug enlicitide, belongs to a class of medications known as PCSK9 inhibitors. Until now, these drugs were only available as injections. Lipfendra is a tablet taken once a day and is the first oral PCSK9 inhibitor to win FDA approval. “Treating cholesterol more aggressively or more fully is…

FDA approves first cholesterol pill to match powerful injectable drugs

Merck’s once-daily Lipfendra offers a pill alternative to injectable cholesterol drugs after Phase 3 trials involving Israeli patients

FDA approves first-of-its-kind cholesterol pill Lipfendra

The FDA has approved Lipfendra, the first oral PCSK9 inhibitor, for the treatment of high cholesterol. Two medical experts explain why this matters.

What to know about the powerful new cholesterol pill

The drug is expected to go on the market in the coming weeks. Read more at straitstimes.com.